Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04016220
Other study ID # University of Monastir
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date May 20, 2019
Est. completion date May 20, 2020

Study information

Verified date July 2019
Source University of Monastir
Contact Soudani Marghli, Professor
Phone 00 216 73 109 019
Email soudani.marghli@rns.tn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Our study is a prospective double-blind randomized study performed in the Emergency Department (ED). The objective of our study was to demonstrate the additive effect of high and repeated doses of inhaled budesonide combined with the standard treatment of acute asthma in adult managed in the ED


Description:

Patients were included in a double-blind, randomized into one of two groups. The experimental group received a first nebulization of 5 mg of terbutaline (Bricanyl®, AstraZeneca : solution of 5mg/ 2 ml ) in association with 0.5 mg of ipratropium bromide (Ipratropium®, AGUETTANT, solution of 0.5 mg/ 2 ml) and 0.5 mg of budesonide (Pulmicort®, AstraZeneca, solution of 0.5 mg/2 ml) followed by repetitive nebulization of 5 mg of terbutaline with 0.5 mg of budesonide at 20, 40, 60 and 120 min. The control group received a first nebulization of 5 mg of terbutaline in association with 0.5 mg of ipratropium bromide and 2 ml of normal saline followed by a repetitive nebulization of 5 mg de terbutaline with 2 ml of normal saline at 20, 40, 60 and 120 min (Figure 1). The placebo and the budesonide were prepared by the pharmacist. All patients received hydrocortisone hemisuccinate (100 mg i.v.) and O2 (7 l/ min) via a nebulizer (Mini nebulizer 40-115510; Peters, France).

Measure The following parameters were measured in each patient immediately before starting the treatment and at 30 minute intervals for 3 hours after presentation: peak expiratory flow (PEF), respiratory rate (RR), heart rate (HR), dyspnea scale, systolic and diastolic blood pressure. PEF was measured with peak flow meter (mini-Wright; Clement Clarke; Harlow, UK). The highest of three values was recorded. HR was measured from continuous monitor. Dyspnea was assessed by the patient's own sensation of respiratory difficulty with a value assigned on a scale of 0 to 3, in which 0 denoted absent, 1 mild, 2 moderate, and 3 severe. At the end of the treatment, the patient was asked to indicate the presence or absence of each of five symptoms: palpitations, tremor, anxiety, headache, and dry mouth. Also, an interviewer determined the duration of symptoms before presentation, which specifically included how long the patient had been wheezing and shorter of breath than usual; a decline in the PEF, if available, was considered. The occurrence of a worsening of ventilator status requiring mechanical ventilation led to interrupt the study protocol. The decision to discharge or admit a patient was made at the end of the protocol (180 minutes) by a senior ED staff without knowledge of previous patient group allocation. Although some patients met discharge criteria during the study, none were discharged until the end of the protocol. Patients were discharged from the ED according to the following criteria: if accessory-muscle use disappeared, if wheezing was judged minimal to completely resolved, if they were free of dyspnea, and if PEF was more than 60% of predicted value. Physicians prescribed oral prednisone (40 mg for 7 days) for all discharged patients.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date May 20, 2020
Est. primary completion date December 20, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria:

- acute asthma

- peak expiratory flow (PEF) rate less than 50% of predicted value

- one or more of the following features were present: accessory muscle activity, a heart rate greater than 110 beats/minute, a respiratory rate greater than 25 breaths/minute, a limited ability to speak

- written informed consent obtained

Exclusion Criteria:

- temperature higher than 38°C

- history of cardiac, hepatic, renal, or other medical disease

- pregnant

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Budesonide
first nebulization of 0.5 mg of budesonide in association with terbutaline and ippratropium bromide followed by repetitive nebulization of 5 mg of terbutaline with 0.5 mg of budesonide at 20, 40, 60 and 120 min.
normal saline
first nebulization of 2ml of normal saline as placebo comparator in association with terbutaline and ippratropium bromide followed by repetitive nebulization of 5 mg of terbutaline with 2 ml of normal saline at 20, 40, 60 and 120 min.

Locations

Country Name City State
Tunisia University of Monastir Monastir

Sponsors (1)

Lead Sponsor Collaborator
University of Monastir

Country where clinical trial is conducted

Tunisia, 

References & Publications (3)

Bateman ED, Fairall L, Lombardi DM, English R. Budesonide/formoterol and formoterol provide similar rapid relief in patients with acute asthma showing refractoriness to salbutamol. Respir Res. 2006 Jan 24;7:13. — View Citation

Guttman A, Afilalo M, Colacone A, Kreisman H, Dankoff J. The effects of combined intravenous and inhaled steroids (beclomethasone dipropionate) for the emergency treatment of acute asthma. The Asthma ED Study Group. Acad Emerg Med. 1997 Feb;4(2):100-6. — View Citation

Rodrigo GJ. Comparison of inhaled fluticasone with intravenous hydrocortisone in the treatment of adult acute asthma. Am J Respir Crit Care Med. 2005 Jun 1;171(11):1231-6. Epub 2005 Mar 11. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary admission rate The decision to discharge or admit a patient was made at the end of the protocol (180 minutes) 3 hours
Secondary Peak expiratory flow Peak expiratory flow (L/min) was measured in each patient immediately before starting the treatment and at 30 minute intervals for 3 hours after presentation. 3 hours
Secondary respiratory rate was measured in each patient immediately before starting the treatment and at 30 minute intervals for 3 hours after presentation. respiratory rate 3 hours
Secondary dyspnea scale Dyspnea was assessed by the patient's own sensation of respiratory difficulty with a value assigned on a scale of 0 to 3, in which 0 denoted absent, 1 mild, 2 moderate, and 3 severe. was measured in each patient immediately before starting the treatment and at 30 minute intervals for 3 hours after presentation: 3 hours
Secondary Hear rate Heart rate was measured in each patient immediately before starting the treatment and at 30 minute intervals for 3 hours after presentation. 3 hours
Secondary tremor incidence of tremor 3 hours
Secondary dry mouth incidence of dry mouth 3 hours
Secondary palpitation incidence of palpitation 3 hours
Secondary headache incidence of headache 3 hours
See also
  Status Clinical Trial Phase
Completed NCT01429415 - Magnesium Nebulization Utilization in Management of Pediatric Asthma Phase 2
Completed NCT01196377 - Optimal Albuterol Regimens for Acute Asthma Exacerbations: DBRCT Pilot Study N/A
Completed NCT00733317 - Budesonide for Emergency Treatment of Acute Wheezing in Children Phase 4
Completed NCT00733473 - Nebulized Budesonide for Children Who Are Hospitalized for Acute Wheezing Phase 4
Completed NCT01695031 - Feasibility of an ED Initiated Online Asthma Management Program for Urban Teens N/A
Active, not recruiting NCT06005337 - Supporting Parents to Choose Wisely N/A
Completed NCT01079000 - Emergency Department (ED)-Directed Interventions to Improve Asthma Outcomes N/A
Completed NCT00922350 - Heliox and Posture in Patients With Asthma N/A
Completed NCT03698630 - Single Dose Oral Dexamethasone Versus Multi-dose Prednisolone in the Treatment of Acute Exacerbations of Asthma in Children Phase 4
Terminated NCT00819637 - A Pilot Study to Determine the Most Effective Dose of Arformoterol for Treating Acute Asthmatic Patients Phase 4
Completed NCT01868113 - Inhaled Corticosteroids in U-5 Children With Acute Respiratory Infection in Uganda: A Randomised Trial Phase 3
Completed NCT01016444 - Acute Asthma Responsiveness and B2 Adrenergic Receptors Polymorphisms
Completed NCT00393367 - Budesonide Inhalation Suspension for Acute Asthma in Children Phase 4
Completed NCT03369119 - Effect of Addition Oral Montelukast to Standard Treatment in Acute Asthma in Hospitalized Preschool Children Phase 4
Completed NCT01304901 - Effect of Addition of Single Dose of Oral Montelukast to Standard Treatment in Acute Asthma in Preschool Children. Phase 4
Completed NCT01403467 - Impact of Continuous Positive Airway Pressure on the Treatment of Acute Asthma Exacerbation Phase 4